Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) has been manufacturing and distributing high-quality therapeutics across the Middle East for four decades.
Variational AI is using its Enki platform to explore uncharted regions of the chemical space, accelerating the discovery and development of transformative therapeutics in collaboration with biopharma partners across various high-need therapeutic areas.
ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced vaccine and therapeutic applications.
This year’s drug development has been characterized by multiple deals signed with companies from China, along with collaborations involving firms specializing in artificial intelligence and antibodies.
Bispecific and multispecific antibodies are gaining momentum in oncology research. They accounted for a quarter of the top 20 highest-grossing deals in the year to date, with many transactions focusing on Chinese assets.
Powered by its industry-leading library of genomic data, covering a comprehensive spectrum of genes, Caris Life Sciences is committed to identifying the best treatments.
The Korea Drug Development Fund (KDDF), Korea’s largest non-dilutive funder of drug research and development (R&D), is advancing Korea’s oncology sector with a globally competitive, modality-diverse pipeline of cancer therapeutics.
By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.
Advances with in vivo cell therapies and adeno-associated viral vectors that deliver gene therapies to organs other than the liver have driven major deals in the past 12 months.
Actithera is pioneering chemistries in radioligand therapy that extend tumor residence time, creating differentiated candidates like its lead fibroblast activation protein-targeted compound.
Adverum Biotechnologies is developing one-time gene therapies aimed at revolutionizing the treatment of patients with wet age-related macular degeneration and other serious ocular disorders.
Candel Therapeutics is driving a paradigm shift in the treatment of solid tumors through the development of novel viral immunotherapies. The company plans to file a Biologics License Application (BLA) for its lead clinical candidate, aglatimagene besadenovec (CAN-2409), for localized prostate cancer in late 2026.
Angiocrine Bioscience uses its propriety platform to harness the reparative powers of vascular endothelial cells and develop advanced therapeutics that repair tissue damage and treat chronic conditions.
DC-Biotech is using its pioneering, proprietary αNKT technology to leverage the unique immunomodulatory properties of natural killer T-cells and mesenchymal stem cells, accelerating the development of regenerative medical products for diseases with unmet need, particularly those related to immune system dysregulation and inflammation.
Biotech firm Syntax Bio aims to transform pluripotent stem cells into clinical therapeutics using its CRISPR-based technology platform called Cellgorithm.
Intravitreal injection of jCyte’s proprietary retinal progenitor cells can halt vision loss and potentially restore sight in patients with retinitis pigmentosa, the leading cause of inherited blindness.
